Although anti–PD-1 and anti–CTLA-4 targeting antibodies, so far, have been ineffective in the treatment of gliomas (57–60), combining known immune checkpoint blockades with novel targets remains a promising strategy. The gene discussed is CTLA4; the disease is central nervous system cancer.